Human and experimental
heart failure is characterized by increases in type-1
protein phosphatase activity, which may be partially attributed to inactivation of its endogenous regulator,
protein phosphatase inhibitor-1. Inhibitor-1 represents a nodal integrator of two major second messenger pathways,
adenosine 3',5'-cyclic monophosphate (cAMP) and
calcium, which mediate its phosphorylation at
threonine 35 and
serine 67, respectively. Here, using recombinant inhibitor-1 wild-type and mutated
proteins, we identified a novel phosphorylation site in inhibitor-1,
threonine 75. This phosphoamino
acid was phosphorylated in vitro by
protein kinase Calpha independently and to the same extent as
serine 67, the previous
protein kinase Calpha-identified site. Generation of specific
antibodies for the phosphorylated and dephosphorylated
threonine 75 revealed that this site is phosphorylated in rat and dog hearts. Adenoviral-mediated expression of the constitutively phosphorylated
threonine 75 inhibitor-1 in isolated myocytes was associated with specific stimulation of type-1
protein phosphatase activity and marked inhibition of the sarcoplasmic
calcium pump affinity for
calcium, resulting in depressed contractility. Thus, phosphorylation of inhibitor-1 at
threonine 75 represents a new mechanism of cardiac contractility regulation, partially through the alteration of sarcoplasmic reticulum
calcium transport activity.